Joseph Stringer
Stock Analyst at Needham
(4.32)
# 443
Out of 4,996 analysts
312
Total ratings
46.76%
Success rate
19.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Buy | $74 → $100 | $90.50 | +10.50% | 15 | Sep 24, 2025 | |
| RNA Avidity Biosciences | Maintains: Buy | $60 → $65 | $42.95 | +51.34% | 18 | Sep 10, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $55 → $70 | $64.09 | +9.22% | 23 | Sep 2, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $377 → $478 | $446.40 | +7.08% | 23 | Jul 31, 2025 | |
| GILD Gilead Sciences | Upgrades: Buy | $133 | $112.10 | +18.64% | 7 | Jul 25, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $72 → $95 | $99.16 | -4.20% | 25 | Jul 9, 2025 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $22 | $24.14 | -8.86% | 23 | Jul 1, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 | $11.78 | +137.69% | 52 | Jun 6, 2025 | |
| VIR Vir Biotechnology | Reiterates: Buy | $14 | $5.49 | +155.01% | 18 | May 22, 2025 | |
| ANNX Annexon | Maintains: Buy | $16 → $11 | $3.37 | +226.41% | 19 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $29 | $22.39 | +29.52% | 20 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $385.74 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $90 | $33.98 | +164.86% | 17 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.40 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.52 | +557.89% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $24.49 | - | 8 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $21.05 | +75.77% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $14.07 | +27.93% | 2 | Aug 24, 2021 |
Cidara Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $74 → $100
Current: $90.50
Upside: +10.50%
Avidity Biosciences
Sep 10, 2025
Maintains: Buy
Price Target: $60 → $65
Current: $42.95
Upside: +51.34%
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $55 → $70
Current: $64.09
Upside: +9.22%
Alnylam Pharmaceuticals
Jul 31, 2025
Maintains: Buy
Price Target: $377 → $478
Current: $446.40
Upside: +7.08%
Gilead Sciences
Jul 25, 2025
Upgrades: Buy
Price Target: $133
Current: $112.10
Upside: +18.64%
Rhythm Pharmaceuticals
Jul 9, 2025
Maintains: Buy
Price Target: $72 → $95
Current: $99.16
Upside: -4.20%
Stoke Therapeutics
Jul 1, 2025
Reiterates: Buy
Price Target: $22
Current: $24.14
Upside: -8.86%
Phathom Pharmaceuticals
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $11.78
Upside: +137.69%
Vir Biotechnology
May 22, 2025
Reiterates: Buy
Price Target: $14
Current: $5.49
Upside: +155.01%
Annexon
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $3.37
Upside: +226.41%
May 7, 2025
Maintains: Buy
Price Target: $40 → $29
Current: $22.39
Upside: +29.52%
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $385.74
Upside: -
Apr 8, 2025
Reiterates: Buy
Price Target: $90
Current: $33.98
Upside: +164.86%
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.40
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.52
Upside: +557.89%
Nov 8, 2024
Reiterates: Hold
Price Target: n/a
Current: $24.49
Upside: -
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $21.05
Upside: +75.77%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $14.07
Upside: +27.93%